Table 4.
The number of attacks and the treatment characteristics in the three groups of patients
| Number of attacks | Number of treated attacks (compliant and non-compliant) | % of treated attacks | Number of vials | Average number of vials per attack | |
|---|---|---|---|---|---|
| Strategy 1 (home-based) | |||||
| Icatibant | 188 | 84 | 44.68% | 93 | 1.11 |
| PdC1-INH | 556 | 435 | 78.24% | 810 | 1.86 |
| Strategy 2 (hospital-based) | |||||
| Hospital-based PdC1-INH | 54 | 26 | 48.15% | 67 | 2.58 |
| Total Strategy 1 | 744 | 519 | 69.76% | 903 | 1.74 |
| Total Strategy 2 | 54 | 26 | 48.15% | 67 | 2.58 |
pdC1-INH plasma-derived C1-esterase inhibitor concentrate